EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Molecular analysis of XPO1 inhibitor and gemcitabine–nab‐paclitaxel combination in KPC pancreatic cancer mouse model

Md Hafiz Uddin iD, Mohammad Najeeb Al-Hallak, Husain Yar Khan, Amro Aboukameel, Yiwei Li, Sahar F Bannoura, Gregory Dyson, Seongho Kim, Yosef Mzannar, Ibrahim Azar, Tanya Odisho, Amr Mohamed und 7 weitere

Clinical and Translational Medicine · 2023

DOI: 10.1002/ctm2.1513 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical and Translational Medicine, 2023. Verfasst von Md Hafiz Uddin und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, Michigan, USA. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Carcinoma, Pancreatic Ductal, Exportin 1 Protein, Drug Combinations. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The majority of pancreatic ductal adenocarcinoma (PDAC) patients experience disease progression while on treatment with gemcitabine and nanoparticle albumin‐bound (nab)‐paclitaxel (GemPac) necessitating the need for a more effective treatment strategy for this refractory disease. Previously, we have demonstrated that nuclear exporter protein exportin 1 (XPO1) is a valid therapeutic target in PDAC, and the selective inhibitor of nuclear export selinexor (Sel) synergistically enhances the efficacy of GemPac in pancreatic cancer cells, spheroids and patient‐derived tumours, and had promising activity in a phase I study.

Methods

Here, we investigated the impact of selinexor–gemcitabine–nab‐paclitaxel (Sel‐GemPac) combination on LSL‐Kras G12D/+ ; LSL‐Trp53 R172H/+ ; Pdx1‐Cre (KPC) mouse model utilising digital spatial profiling (DSP) and single nuclear RNA sequencing (snRNAseq).

Results

Sel‐GemPac synergistically inhibited the growth of the KPC tumour‐derived cell line. The Sel‐GemPac combination reduced the 2D colony formation and 3D spheroid formation. In the KPC mouse model, at a sub‐maximum tolerated dose (sub‐MTD) , Sel‐GemPac enhanced the survival of treated mice compared to controls ( p < .05). Immunohistochemical analysis of residual KPC tumours showed re‐organisation of tumour stromal architecture, suppression of proliferation and nuclear retention of tumour suppressors, such as Forkhead Box O3a (FOXO3a). DSP revealed the downregulation of tumour promoting genes such as chitinase‐like protein 3 (CHIL3/CHI3L3/YM1) and multiple pathways including phosphatidylinositol 3'‐kinase‐Akt (PI3K‐AKT) signalling. The snRNAseq demonstrated a significant loss of cellular clusters in the Sel‐GemPac‐treated mice tumours including the CD44+ stem cell population.

Conclusion

Taken together, these results demonstrate that the Sel‐GemPac treatment caused broad perturbation of PDAC‐supporting signalling networks in the KPC mouse model. Highlights The majority of pancreatic ductal adenocarcinoma (PDAC) patients experience disease progression while on treatment with gemcitabine and nanoparticle albumin‐bound (nab)‐paclitaxel (GemPac). Exporter protein exportin 1 (XPO1) inhibitor selinexor (Sel) with GemPac synergistically inhibited the growth of LSL‐KrasG12D/+; LSL‐Trp53R172H/+; Pdx1‐Cre (KPC) mouse derived cell line and enhanced the survival of mice. Digital spatial profiling shows that Sel‐GemPac causes broad perturbation of PDAC‐supporting signalling in the KPC model.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pancreatic NeoplasmsCarcinoma, Pancreatic DuctalExportin 1 ProteinDrug CombinationsAnimalsMiceDisease Models, AnimalGemcitabinePaclitaxelHydrazinesTriazolesTumor MicroenvironmentSingle-Cell Gene Expression AnalysisHumans

Stichwörter der Autor:innen

KPC mouse modeldigital spatial profilinggemcitabinenab-paclitaxelpancreatic cancerselinexorsnRNAseq

Substanzen

Xpo1 protein, mouseExportin 1 ProteinGemcitabinePaclitaxelselinexorHydrazinesTriazolesDrug Combinations

Autor:innen und Institutionen

  • Department of Oncology, Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, Michigan, USA.
  • Detroit Medical Center, Detroit, Michigan, USA.
  • UH Seidman Cancer Center, University Hospitals, Case Western Reserve University, Cleveland, Ohio, USA.
  • Karyopharm Therapeutics Inc., Newton, Massachusetts, USA.
  • Department of Pathology, Wayne State University School of Medicine, Detroit, Michigan, USA.
  • Henry Ford Cancer Institute, Detroit, Michigan, USA.

ORCID-Profile: Md Hafiz Uddin

Förderung

  • NCI NIH HHS

Zitieren

APA

Uddin, M. H., Al-Hallak, M. N., Khan, H. Y., Aboukameel, A., Li, Y., Bannoura, S. F., Dyson, G., Kim, S., Mzannar, Y., Azar, I., Odisho, T., Mohamed, A., Landesman, Y., Kim, S., Beydoun, R., Mohammad, R. M., Philip, P. A., Shields, A. F., & Azmi, A. S. (2023). Molecular analysis of XPO1 inhibitor and gemcitabine–nab‐paclitaxel combination in KPC pancreatic cancer mouse model. Clinical and Translational Medicine. https://doi.org/10.1002/ctm2.1513

Vancouver

Uddin MH, Al-Hallak MN, Khan HY, Aboukameel A, Li Y, Bannoura SF, et al. Molecular analysis of XPO1 inhibitor and gemcitabine–nab‐paclitaxel combination in KPC pancreatic cancer mouse model. Clinical and Translational Medicine. 2023. doi:10.1002/ctm2.1513

BibTeX
@article{Uddin2023,
  author = {Uddin, Md Hafiz and Al-Hallak, Mohammad Najeeb and Khan, Husain Yar and Aboukameel, Amro and Li, Yiwei and Bannoura, Sahar F and Dyson, Gregory and Kim, Seongho and Mzannar, Yosef and Azar, Ibrahim and Odisho, Tanya and Mohamed, Amr and Landesman, Yosef and Kim, Steve and Beydoun, Rafic and Mohammad, Ramzi M and Philip, Philip A and Shields, Anthony F and Azmi, Asfar S},
  title = {Molecular analysis of XPO1 inhibitor and gemcitabine–nab‐paclitaxel combination in KPC pancreatic cancer mouse model},
  journal = {Clinical and Translational Medicine},
  year = {2023},
  doi = {10.1002/ctm2.1513}
}
Kostenlos starten →